Back

Generation of an induced pluripotent stem cell line from a patient with immune checkpoint inhibitor-induced myocarditis and concurrent type I diabetes

Lee, M. K.; Vitale, M. R.; Sun, Y.; Wagner, N. S.; Sundar, H. A.; Sun, S.; Ramchandran, A.; Khatua, S.; Chou, H.; Huang, Y. V.; Zhuge, Y.; Wu, J. C.; Zhu, H.

2026-08-27 developmental biology
10.64898/2026.08.26.746482 bioRxiv
Show abstract

Immune checkpoint inhibitor-induced myocarditis (ICIM) is a severe immune-related adverse event with heterogeneous clinical presentations and potential genetic susceptibility. Here, we established a human induced pluripotent stem cell (iPSC) line from an ICIM patient with an HLA-type distinct from previously reported line, who developed concurrent type I diabetes following ICI treatment. This line exhibited typical morphology, normal female karyotype, pluripotency, trilineage differentiation into all three germ layers, Sendai virus clearance, and no mycoplasma contamination. Given the fulminant nature and diverse clinical presentations of ICIM, expanding the repertoire of iPSC lines are critical for investigating ICIM heterogeneity and its underlying mechanisms.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.